Antithrombotic dose: Some observations from published clinical trials

Simon B. Dimmitt, Christopher N. Floyd, Robin E. Ferner

Research output: Contribution to journalArticle

Abstract

The clinical doses of antithrombotics—antiplatelet and anticoagulant agents—need to balance efficacy and safety. It is not clear from the published literature how the doses currently used in clinical practice have been derived from preclinical and clinical data. There are few large randomised controlled trials (RCTs) that compare outcomes with different doses vs placebo. For newer antithrombotics, RCT doses appear to have been chosen to maximise the probability of demonstrating noninferiority when compared to established agents such as warfarin or clopidogrel. Data from RCTs show that aspirin is an effective antithrombotic at doses below 75 mg daily, and that direct oral anticoagulants reduce the risk of stroke in patients with coronary disease at doses 1/4 of those recommended in atrial fibrillation. Lower doses than those currently recommended are safer and still maintain substantial efficacy.

Original languageEnglish
JournalBritish Journal of Clinical Pharmacology
DOIs
Publication statusE-pub ahead of print - 3 May 2019

Fingerprint

Randomized Controlled Trials
clopidogrel
Clinical Trials
Anticoagulants
Warfarin
Atrial Fibrillation
Aspirin
Coronary Disease
Stroke
Placebos
Safety

Cite this

@article{315b5a3c33a147959c5be71e3aef92e7,
title = "Antithrombotic dose: Some observations from published clinical trials",
abstract = "The clinical doses of antithrombotics—antiplatelet and anticoagulant agents—need to balance efficacy and safety. It is not clear from the published literature how the doses currently used in clinical practice have been derived from preclinical and clinical data. There are few large randomised controlled trials (RCTs) that compare outcomes with different doses vs placebo. For newer antithrombotics, RCT doses appear to have been chosen to maximise the probability of demonstrating noninferiority when compared to established agents such as warfarin or clopidogrel. Data from RCTs show that aspirin is an effective antithrombotic at doses below 75 mg daily, and that direct oral anticoagulants reduce the risk of stroke in patients with coronary disease at doses 1/4 of those recommended in atrial fibrillation. Lower doses than those currently recommended are safer and still maintain substantial efficacy.",
author = "Dimmitt, {Simon B.} and Floyd, {Christopher N.} and Ferner, {Robin E.}",
year = "2019",
month = "5",
day = "3",
doi = "10.1111/bcp.13968",
language = "English",
journal = "British Journal Clinical Pharmacology",
issn = "0306-5251",
publisher = "John Wiley & Sons",

}

Antithrombotic dose : Some observations from published clinical trials. / Dimmitt, Simon B.; Floyd, Christopher N.; Ferner, Robin E.

In: British Journal of Clinical Pharmacology, 03.05.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Antithrombotic dose

T2 - Some observations from published clinical trials

AU - Dimmitt, Simon B.

AU - Floyd, Christopher N.

AU - Ferner, Robin E.

PY - 2019/5/3

Y1 - 2019/5/3

N2 - The clinical doses of antithrombotics—antiplatelet and anticoagulant agents—need to balance efficacy and safety. It is not clear from the published literature how the doses currently used in clinical practice have been derived from preclinical and clinical data. There are few large randomised controlled trials (RCTs) that compare outcomes with different doses vs placebo. For newer antithrombotics, RCT doses appear to have been chosen to maximise the probability of demonstrating noninferiority when compared to established agents such as warfarin or clopidogrel. Data from RCTs show that aspirin is an effective antithrombotic at doses below 75 mg daily, and that direct oral anticoagulants reduce the risk of stroke in patients with coronary disease at doses 1/4 of those recommended in atrial fibrillation. Lower doses than those currently recommended are safer and still maintain substantial efficacy.

AB - The clinical doses of antithrombotics—antiplatelet and anticoagulant agents—need to balance efficacy and safety. It is not clear from the published literature how the doses currently used in clinical practice have been derived from preclinical and clinical data. There are few large randomised controlled trials (RCTs) that compare outcomes with different doses vs placebo. For newer antithrombotics, RCT doses appear to have been chosen to maximise the probability of demonstrating noninferiority when compared to established agents such as warfarin or clopidogrel. Data from RCTs show that aspirin is an effective antithrombotic at doses below 75 mg daily, and that direct oral anticoagulants reduce the risk of stroke in patients with coronary disease at doses 1/4 of those recommended in atrial fibrillation. Lower doses than those currently recommended are safer and still maintain substantial efficacy.

UR - http://www.scopus.com/inward/record.url?scp=85068511614&partnerID=8YFLogxK

U2 - 10.1111/bcp.13968

DO - 10.1111/bcp.13968

M3 - Article

JO - British Journal Clinical Pharmacology

JF - British Journal Clinical Pharmacology

SN - 0306-5251

ER -